Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunogenic compositions for pneumonia chlamydia

A technology of Chlamydia pneumoniae and immunogenic fragments, which is applied in the field of immunology and vaccinology, and can solve the problem of incompleteness

Inactive Publication Date: 2007-06-20
CHIRON CORP
View PDF66 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Other common problems may arise from the degree of allelic variation and regulatory proteins that are not always expressed in all Chlamydia cells or in all Chlamydia isolates

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunogenic compositions for pneumonia chlamydia
  • Immunogenic compositions for pneumonia chlamydia
  • Immunogenic compositions for pneumonia chlamydia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[1493] Embodiment 1 (in vitro study)

[1494] Screening of antisera based on in vitro neutralizing properties

[1495]After a genome-wide screen for proteins likely to be located on the cell surface of C. pneumoniae, we recently reported (25) that antisera to 53 recombinant Chlamydia antigens were able to bind to the cell surface of C. pneumoniae in a FACS assay. In order to test whether some FACS-positive antigens can interfere with the infectivity of EBs in vitro, we prepared mouse antisera against recombinant FACS-positive antigens and evaluated the effect of each antiserum on the infectivity of purified EBs to LLC-MK2 cell monolayers. influences. First, infectious EBs were incubated with antiserum and then used to infect cell monolayers in 24-well multiwell titer plates, similarly to control samples where EBs were: i) treated with buffer only, or ii) treated with the same dilution The corresponding pre-immune mouse serum treatment.

[1496] Result I

[1497] Using this...

Embodiment 2

[1507] Example 2 (in vivo studies)

[1508] Evaluation of antiserum specificity of Cpn protein extracts by 2D immunoblot analysis

[1509] To investigate whether the neutralizing activity observed in in vitro infection of LLC-MK2 cell monolayers was in fact due to antibody binding to selected C. The specificity of the antisera was evaluated by Western blot analysis.

[1510] Specifically, this analysis was performed on six antigens (Pmp2, Pmp10, Eno, ArtJ, HtrA and OmpH-like antigens) visible in the 2D map of EB total protein (Montigiani et al., 2002 Infection and Immunity 70:368-379). EB total protein was analyzed by 2D electrophoresis using two different pH intervals (pH 3-10 non-linear, pH 4-7, respectively), since it has previously been shown that one of the above pH intervals rather than the other is better for detecting the protein under study. some egg whites. Four gels were run in parallel at each pH interval. One gel was stained with Coomassie blue to visualize pr...

Embodiment 3

[1517] In vivo evaluation of in vitro neutralizing antigens in a hamster model of systemic infection

[1518] We recently described a novel hamster model of systemic C. pneumoniae infection in which replicating C. pneumoniae is disseminated by macrophages and accumulates in the spleen (34). We therefore asked the question whether the in vitro neutralizing antigens we identified were also protective in vivo in this model. To this end, 8 hamsters were immunized with 10 in vitro neutralizing recombinant antigens 3 times subcutaneously during 3 weeks, and two weeks later with 2 × 10 8 Cpn EB stimulation. Spleen infection was assessed 7 days after challenge. Protection specifically induced by putative vaccine candidates was measured as the difference between the mean number of infectious Chlamydia recovered from control animals and the number of Chlamydia recovered from animals immunized with recombinant Chlamydia antigens.

[1519] result 3

[1520] The results of spleen prote...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to polypeptides for use as an autotransporter antigen. The invention further relates to methods and uses of a polypeptide for an autotransporter function in preparation of a medicament for the prevention or treatment of a Chlamydia pneumoniae infection or for the preparation of an assay for the diagnosis of a Chlamydia pneumoniae infection in an individual. Also, a method is provided for raising an immune response in an individual by administering to the individual a polypeptide for use as an autotransporter antigen.

Description

[0001] This application claims priority over U.S. Provisional Application 60 / 542,832, filed March 2, 2004; U.S. Provisional Application 60 / 643,110, filed January 12, 2005; and U.S. Provisional Application 60 / 644,552, filed January 19, 2005 right, which is incorporated herein by reference in its entirety. [0002] All documents cited herein are hereby incorporated by reference in their entirety. field of invention [0003] The present invention relates to the fields of immunology and vaccinology. In particular, the present invention relates to immunogenic compositions comprising combinations of immunogenic molecules from Chlamydia pneumoniae. Background technique [0004] Bacteria of the genus Chlamydia (and Chlamydophila), according to a recently proposed but still debated reclassification of the family Chlamydiaceae (Bush et al. (2001), Int J Syst Evol Microbiol 51:203-20; Everett et al. (1999) Int J Syst Bacteriol 49: Pt2 415-40; Schachter et al. (2001) Int J Syst Evol M...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/118A61K39/00C12P21/04C07H21/04
Inventor G·格兰迪R·朱利奥
Owner CHIRON CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com